One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: The Avantage study;Suivi sur un an dans les conditions de pratique courante d'une cohorte de patients diabétiques de type 2 traités par rosiglitazone : l'étude Avantage

Annales d'Endocrinologie

Volumn 69, Issue 1, 2008, Pages 36-46

  Slama, G ^a   Eschwege E ^b   Bernard, M H ^c   Grimaldi, A ^d   Oppert, J M ^d   Pouchain, D ^c   Begaud B ^e  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c université Victor Segalen Bordeaux 2 ^*  (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Adverse events; Oral antidiabetic agents; Rosiglitazone; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; FUROSEMIDE; GLITAZONE DERIVATIVE; METFORMIN; ROSIGLITAZONE; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES CONTROL; DIASTOLIC BLOOD PRESSURE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FEMALE; FOLLOW UP; FRANCE; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT GAIN;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 41549132570     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2007.10.024     Document Type: Article

References (46)

1. Girard J. Mécanisme d'action des thiazolidinediones. Diabetes Metab 27 (2001) 271-278
2. Girard J. PPARγ et insulino-résistance. Ann Endocrinol 63 (2002) 1S19-1S22
3. Lebovitz H.E. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol 90 Suppl. (2002) 34G-41G
4. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14 (2003) 137-145
5. Larsen T.M., Toubro S., and Astrup A. PPARγ agonists: adipogenic treatment of type II diabetes. Int J Obes 27 (2003) 147-161
6. Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (2004) S43-S50
7. Blicklé J.F. Place des thiazolidinediones dans le traitement du diabète de type 2. Presse Med 33 (2004) 1034-1040
8. Pégorier J.P., and Girard J. Thiazolidinediones et insulino-sensibilité : rôle du récepteur nucléaire PPARγ. Ann Endocrinol 65 (2004) 65-72
9. Werner A.L., and Travaglini M.T. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21 (2001) 1082-1099
10. Wagstaff A.J., Goa K.L., and Rosiglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 62 (2002) 1805-1837
11. Blickle J.F. Rosiglitazone : les éléments cliniques. Ann Endocrinol 63 (2002) 1S27-1S33
12. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications. Recommandations de l'ANAES. Diabetes Metab 1999; 25(Suppl. 2):1-64.
13. Programme de Santé Publique sur la prise en charge du diabète de type 2. La prise en charge des diabétiques exclusivement traités par hypoglycémiants oraux en 1999. Données du Régime général de l'Assurance Maladie. Caisse nationale de l'Assurance Maladie des salariés-sécurité sociale. Octobre 2000. 91 p.
14. Fagot-Campagna A., Simon D., Varroud-Vial M., et al. comité scientifique d'Entred. Caractéristiques des personnes diabétiques traitées et adéquation du suivi médical du diabète aux recommandations officielles. Entred 2001. Bull Epidemiol Hebdo 49-50 (2003) 238-239
15. Detournay B., Vauzelle-Kervroedan F., Charles M.A., et al. Épidémiologie, prise en charge et coût du diabète de type 2 en France en 1998. Diabetes Metab 25 (1999) 356-365
16. Charpentier G., Genès N., Vaur L., et al. ESPOIR Diabetes Study Investigators. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 29 (2003) 152-158
17. Monnier L., Grimaldi A., Charbonnel B., et al. Management of French patients with type 2 diabetes mellitus in medical general practice: Report of the MEDIAB observatory. Diabetes Metab 30 (2004) 35-42
18. Charbonnel B., Dumenil V., Paillasson S., Baleydier A., and Baigts F. Management of type 2 diabetes patients in France: any difference among physicians? The observational epidemiologic SIMPA study. Diabetologia 47 Suppl. 1 (2004) A 121 [abstract PS-317]
19. Prévost G., Pham T.M., Mounier-Vehier C., and Fontaine P. Control of cardiovascular risk in patients with type 2 diabetes and hypertension in a French national study (Phenomen). Diabetes Metab 31 (2005) 479-485
20. Romon I., Fosse S., Weill A., Varroud-Vial M., and Fagot-Campagna A. Prévalence des complications macrovasculaires et niveau de risque vasculaire des diabétiques en France. étude Entred 2001. Bull Epidemiol Hebdo 12-13 (2005) 46-48
21. Raccah D., Bailleau C., Vexiau P., Vaur L., and Eschwège E. Blood glucose control in Type 2 diabetic patients treated with one oral hypoglycemic agent: results from a nationwide French Survey. Diabetologia 47 Suppl. 1 (2004) A120 [abstract PS-314]
22. Rosak C., Petzoldt R., Wolf R., Reblin T., Dehmel B., and Seidel D. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract 59 (2005) 1131-1136
23. ® (rosiglitazone). Janvier 2005.
24. Le Feuvre C. Effets cardiovasculaires de la rosiglitazone. Presse Med 33 (2004) 735-745
25. Laville M., and Andreelli F. Mécanismes de la prise de poids en cas de normalisation glycémique. Diabetes Metab 26 (2000) 42-45
26. Scheen A. Glitazones et prise de poids. Ann Endocrinol 63 (2002) 1S41-1S44
27. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 24 (2001) 758-767
28. Guerci B. Données cliniques nouvelles sur les glitazones. Ann Endocrinol 66 (2005) 1S45-1S58
29. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36.
30. Sutton M.S.J., Rendell M., Dandona P., et al., Rosiglitazone Clinical Trials Study Group. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25 (2002) 2058-2064
31. Wilding J., Dargie H., Hildebrandt P., et al. Rosiglitazone administered to patients with type 2 diabetes and class I/II congestive heart failure does not adversely affect echocardiographic structure or function parameters. Diabetes 54 Suppl. 1 (2005) A20 [abstract 80-OR]
32. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003) 2941-2948
33. Karalliedde J., Buckingham R., Starkie M., Lorand D., Stewart M., Viberti G., and Rosiglitazone Fluid Retention Study Group. Effects of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 17 (2006) 3482-3490
34. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
35. Tiikkainen M., Häkkinen A.M., Korsheninnikova E., Nyman T., Mäkimattila S., and Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
36. Ratziu V., Tahiri M., and Bonyhay L. La stéatohépatite non alcoolique. Ann Endocrinol 66 (2005) 1S71-1S80
37. Utzschneider K.M., and Kahn S.E. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91 (2006) 4753-4761
38. Van Wijk J.P.H., De Koning E.J.P., Martens E.P., and Rabelink T.J. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 23 (2003) 1744-1749
39. Chiquette F., Ramirez G., and DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164 (2004) 2097-2104
40. Freed M.I., Ratner R., Marcovina S.M., et al. Rosiglitazone Study 108 Investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90 (2002) 947-952
41. Yu D., Murdoch S.J., Marcovina S.M., et al. Effect of rosiglitazone on lipid metabolism in type 2 diabetes mellitus patients who were predominant type B LDL and on statins. Diabetes 53 Suppl. 2 (2004) A233 [abstract 951-P]
42. Deray G., Izzedine H., Launay-Vacher V., and Bagnis C. Rein et glitazones. Ann Endocrinol 66 (2005) 1S81-1S90
43. Bakris G., Viberti G., Weston W.M., Heise M., Porter L.E., and Freed M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17 (2003) 7-12
44. Serafidis P.A., lasaridis A.N., Nilsson P.M., et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 22 (2004) 1769-1777
45. Beck-Nielsen H., Hanefeld M., Komadja M., et al. Randomized controlled trial of the effect of rosiglitazone in combination therapy on ambulatory blood pressure in people with type 2 diabetes mellitus followed for 12 months. Diabetologia 48 Suppl. 1 (2005) A279 [Abstract PS768]
46. AFSSAPS-HAS. Recommandation Professionnelle. Traitement médicamenteux du diabète de type 2 (Actualisation). Novembre 2006. Recommandation de Bonne Pratique (Synthèse. Recommandations. Argumentaire). Diabetes Metab 2007;33(1-part 2):1S1-1S105.